Business Context and Reporting Period
This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on December 22, 2015, covering events that occurred on December 17, 2015. The filing details the entry into material definitive employment agreements with three key executives and the adoption of amendments to the Company's Bylaws to align with corporate governance best practices.
Key Financial Metrics and Compensation
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. Financial data is limited to the compensation terms outlined in the new employment agreements:
- Brian Bernick (Chief Clinical Officer): Base salary of $425,000; annual cash bonus targeted at 50% of base salary; grant of options to purchase 325,000 shares.
- Michael Donegan (VP, Finance): Base salary of $290,000; annual cash bonus targeted at 25% of base salary; grant of options to purchase 100,000 shares.
- Mitchel Krassan (Chief Strategy and Performance Officer): Base salary of $300,000; annual cash bonus targeted at 50% of base salary; grant of options to purchase 150,000 shares.
Material Changes
The primary material changes reported are:
- Executive Retention: Execution of one-year renewable employment agreements for Dr. Bernick, Mr. Donegan, and Mr. Krassan, formalizing their roles and compensation structures.
- Severance Provisions: Establishment of standardized severance packages for all three executives, including 12 months of base salary, targeted bonus awards, insurance continuation, and accelerated vesting of unvested equity in the event of termination without cause or resignation for good reason.
- Corporate Governance: Adoption of the First Amendment to the Bylaws to implement advance notice requirements for stockholder proposals and director nominations, and to clarify procedures for written consents and director removal.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risks and contingencies identified relate to the new contractual obligations:
- Compensation Liability: The Company has committed to significant cash and equity compensation, including potential severance liabilities totaling up to 12 months of salary and bonuses for the named executives.
- Restrictive Covenants: The agreements include non-competition and non-solicitation provisions.
- Governance Changes: The Bylaw amendments introduce stricter procedural requirements for stockholder actions and director nominations.
Investor Verification Checklist
- Verify the total number of shares outstanding to assess the dilution impact of the 575,000 new stock options granted.
- Review the Company's cash position to ensure it can support the new annual salary obligations and potential severance payouts.
- Examine the specific vesting schedules for the granted options, which are not detailed in this summary but are contained in the attached exhibits.
- Confirm the specific terms of the "good cause" and "good reason" definitions within the employment agreements to understand the triggers for severance.